These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
136 related items for PubMed ID: 10689875
1. Acute myeloid leukemia in the elderly:--159 Nagoya case studies--Nagoya Cooperative Study Group for Elderly Leukemia. Nagura E, Minami S, Nagata K, Morishita Y, Takeyama H, Sao H, Suzuki H, Naoe T, Yokomaku S, Mizuno H, Murase T, Hirabayashi N, Takeo T, Tanimoto M, Kawashima K, Saito H. Nagoya J Med Sci; 1999 Nov; 62(3-4):135-44. PubMed ID: 10689875 [Abstract] [Full Text] [Related]
2. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A. Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346 [Abstract] [Full Text] [Related]
3. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study. Behringer B, Pitako JA, Kunzmann R, Schmoor C, Behringer D, Mertelsmann R, Lübbert M. Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497 [Abstract] [Full Text] [Related]
4. [Should patients over 65 years old with acute myeloid leukemia be treated with myelosuppressive chemotherapy?]. Spataro V, Cometta A, Glauser MP, Schapira M, Grob JP. Schweiz Med Wochenschr; 1995 Mar 04; 125(9):429-32. PubMed ID: 7892571 [Abstract] [Full Text] [Related]
5. [Clinical significance of micromegakaryocytes in de novo AML]. Kobayashi S, Seki K, Katayama N, Akiba C, Yamamoto T, Sakai K, Yamaguchi M, Maruta A, Noguchi T, Ogawa K. Rinsho Ketsueki; 1993 Mar 04; 34(3):313-20. PubMed ID: 8479083 [Abstract] [Full Text] [Related]
6. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience. Aguilera DG, Vaklavas C, Tsimberidou AM, Wen S, Medeiros LJ, Corey SJ. J Pediatr Hematol Oncol; 2009 Nov 04; 31(11):803-11. PubMed ID: 19801947 [Abstract] [Full Text] [Related]
7. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group. J Clin Oncol; 2003 Sep 15; 21(18):3440-6. PubMed ID: 12668650 [Abstract] [Full Text] [Related]
8. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. Oriol A, Ribera JM, Esteve J, Guàrdia R, Brunet S, Bueno J, Pedro C, Llorente A, Tormo M, Besalduch J, Sánchez JM, Batlle M, Vivancos P, Carreras E, Vilà JM, Julià A, Sierra J, Montserrat E, Feliu E, CETLAM AML-99. Haematologica; 2004 Jul 15; 89(7):791-800. PubMed ID: 15257930 [Abstract] [Full Text] [Related]
9. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Mauritzson N, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z, Björk J, Strömberg U, Nilsson PG, Mitelman F, Hagmar L, Johansson B. Leukemia; 2002 Dec 15; 16(12):2366-78. PubMed ID: 12454741 [Abstract] [Full Text] [Related]
10. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Gupta V, Chun K, Yi QL, Minden M, Schuh A, Wells R, Brandwein J. Cancer; 2005 May 15; 103(10):2082-90. PubMed ID: 15830348 [Abstract] [Full Text] [Related]
11. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR. J Natl Cancer Inst; 2007 Feb 07; 99(3):196-205. PubMed ID: 17284714 [Abstract] [Full Text] [Related]
12. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001. Alymara V, Tzouvara E, Vartholomatos G, Chaidos A, Tsiara S, Bourantas KL. J Exp Clin Cancer Res; 2004 Sep 07; 23(3):447-54. PubMed ID: 15595635 [Abstract] [Full Text] [Related]
13. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years. De Witte T, Muus P, De Pauw B, Haanen C. Bone Marrow Transplant; 1989 Dec 07; 4 Suppl 3():33-5. PubMed ID: 2697396 [Abstract] [Full Text] [Related]
14. Long-term outcomes of de novo acute myeloid leukemia in Thai patients. Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V. J Med Assoc Thai; 2009 Sep 07; 92(9):1143-9. PubMed ID: 19772172 [Abstract] [Full Text] [Related]
15. Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis. Okamoto T, Kanamaru A, Shimazaki C, Motoji T, Takemoto Y, Takahashi M, Fukushima T, Takeshita A, Kusumoto GS, Kishimoto Y, Yorimitsu S, Tsukuda K, Uike N, Arima N, Ohno R. Int J Hematol; 2000 Aug 07; 72(2):200-5. PubMed ID: 11039669 [Abstract] [Full Text] [Related]
16. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Greco M, D'Alò F, Scardocci A, Criscuolo M, Fabiani E, Guidi F, Di Ruscio A, Migliara G, Pagano L, Fianchi L, Chiusolo P, Hohaus S, Leone G, Voso MT. Blood Cells Mol Dis; 2010 Oct 15; 45(3):181-5. PubMed ID: 20655775 [Abstract] [Full Text] [Related]
17. [Diagnosis and treatment strategy for de novo AML with trilineage myelodysplasia]. Kuriyama K. Rinsho Ketsueki; 1994 Mar 15; 35(3):267-71. PubMed ID: 8158847 [Abstract] [Full Text] [Related]
18. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Aguayo A, Kantarjian HM, Estey EH, Giles FJ, Verstovsek S, Manshouri T, Gidel C, O'Brien S, Keating MJ, Albitar M. Cancer; 2002 Nov 01; 95(9):1923-30. PubMed ID: 12404286 [Abstract] [Full Text] [Related]
19. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission. Ferrara F, Morabito F, Latagliata R, Martino B, Annunziata M, Oliva E, Schiavone EM, Pollio F, Palmieri S, Gianfaldoni G, Leoni F. Haematologica; 2001 Aug 01; 86(8):814-20. PubMed ID: 11522537 [Abstract] [Full Text] [Related]
20. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype]. Mi YC, Xue YP, Yu WJ, Liu SH, Zhao YZ, Meng QX, Bian SG, Wang JX. Zhonghua Xue Ye Xue Za Zhi; 2005 Dec 01; 26(12):705-9. PubMed ID: 16620570 [Abstract] [Full Text] [Related] Page: [Next] [New Search]